Regulus Therapeutics Operating Income

Regulus Therapeutics (RGLS) currently reports a operating income of $-52M as of March 2025. That compares with $-33M in the prior-year period — down 58.9% year over year. Use the charts on this page to explore Regulus Therapeutics's operating income history and peer comparisons.

Regulus Therapeutics's operating income decreased from $-33M to $-52M — a 58.9% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regulus Therapeutics reported $-52M in operating income as of March 2025. That compares with $-33M in the prior-year period — down 58.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-52M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Regulus Therapeutics, and consider following RGLS for alerts when major investors trade the stock.

Regulus Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-52M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGLS with unrelated industries.